Early Returns on Small Molecule Therapeutics for SARS-CoV-2

ACS Infect Dis. 2021 Jun 11;7(6):1298-1302. doi: 10.1021/acsinfecdis.0c00874. Epub 2021 Jan 8.

Abstract

The COVID-19 pandemic has generated an unprecedented response within the scientific community. Extraordinary efforts have been undertaken to identify potential new therapeutics to treat SARS-CoV-2 infection spanning traditional medicinal chemistry, repurposing, and computational approaches. The breadth of the effort and rapid progression of many small molecules to clinical testing provide an opportunity to determine what chemical and testing approaches have been the most efficient in identifying potential treatments and how this may inform preparation for future pandemics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Drug Repositioning
  • Humans
  • Pandemics*
  • SARS-CoV-2

Substances

  • Antiviral Agents